Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN)

Clinical Journal of Pain

Volumn 29, Issue 4, 2013, Pages 281-288

  Sang, Christine N ^a   Sathyanarayana, Rekha ^b   Sweeney, Michael ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Pharmacokinetics Depomed Inc   (United States)

Author keywords

Extended release; Gabapentin; Pain; Postherpetic neuralgia

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SLEEP; SOMNOLENCE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84874939151     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318258993e     Document Type: Article

References (20)

1. Dubinsky RM, Kabbani H, El-Chami Z, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63: 959-965. (Pubitemid 39287901)
2. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J. Neurosci. 2001;21: 1868-1875. (Pubitemid 32221370)
3. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha(2)delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303: 1199-1205. (Pubitemid 35424406)
4. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin - calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142: 13-16.
5. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (Shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84: 274-280.
6. Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7: 1581-1595. (Pubitemid 350106836)
7. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46: 409-427. (Pubitemid 23292119)
8. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels. Plasma Pharm Res. 1993; 10: 276-281. (Pubitemid 23041744)
9. Gabapentin extended-release. Drugs R D. 2007;8: 317-320.
10. Gordi T, Hou E, Kasichayanula S, et al. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate- release tablets: a randomized, open-label, multipledose, three-way crossover, exploratory study in healthy subjects. Clin Ther. 2008;30: 909-916. (Pubitemid 351799872)
11. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebocontrolled clinical trial. Clin J Pain. 2009;25: 185-192.
12. Wallace M, Irving G, Cowles V. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Invest. 2010;30: 765-776.
13. Neurontin Prescribing Information. Available at: http:// www.pfizer.com/files/products/uspi-neurontin.pdf. Accessed November 2010.
14. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280: 1837-1842. (Pubitemid 28544424)
15. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94: 215-224. (Pubitemid 33016615)
16. Sabatowski R, Gá lvez R, Cherry DA, et al. 1008-045 Study Group: pregabalin reduces pain and improves sleep and mood disturbances in subjects with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004; 109: 26-35. (Pubitemid 38479767)
17. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60: 1274-1283. (Pubitemid 36460982)
18. Odrcich M, Bailey JM, Cahill CM, et al. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain. 2006;120: 207-212. (Pubitemid 43077184)
19. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18: 350-354. (Pubitemid 35291575)
20. Chen C, Cowles V, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol. 2011;51: 346-358.